Mauna Kea: positive results in pneumology boost share price
According to the data, published in the peer-reviewed journal Respiration, the Cellvizio platform is more accurate and safer than X-ray fluoroscopy in guiding transbronchial cryobiopsy, enabling improved diagnosis of diffuse interstitial lung disease.
The study - carried out on 80 patients between January and November 2022 - shows a significantly higher rate of diagnosis (95% vs. 80%), as well as a 30% reduction in operating time, a 45% reduction in bleeding and, in particular, a much lower incidence of pneumothorax (0% vs. 25%), compared with the group using fluoroscopy.
Listed on the Paris Bourse, Mauna Kea shares gained 2% on Tuesday following the publication of these data.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction